Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells $23,317.00 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.00, for a total transaction of $23,317.00. Following the transaction, the chief executive officer now directly owns 74,123 shares of the company’s stock, valued at $518,861. This represents a 4.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ ATRA traded up $0.18 during midday trading on Wednesday, reaching $7.31. The company’s stock had a trading volume of 28,201 shares, compared to its average volume of 266,345. The company has a market cap of $42.11 million, a P/E ratio of -0.28 and a beta of 0.46. The business’s 50 day moving average price is $10.09 and its two-hundred day moving average price is $9.75. Atara Biotherapeutics, Inc. has a fifty-two week low of $5.40 and a fifty-two week high of $20.81.

Analysts Set New Price Targets

ATRA has been the subject of several recent analyst reports. Canaccord Genuity Group cut their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, January 17th. RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Atara Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics during the fourth quarter valued at approximately $48,000. Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics during the 4th quarter worth $169,000. Citadel Advisors LLC boosted its stake in Atara Biotherapeutics by 2.6% in the fourth quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock valued at $3,558,000 after buying an additional 6,873 shares in the last quarter. Bank of America Corp DE grew its position in Atara Biotherapeutics by 0.8% in the fourth quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock valued at $2,731,000 after acquiring an additional 1,543 shares during the last quarter. Finally, Northern Trust Corp acquired a new position in Atara Biotherapeutics during the fourth quarter worth about $149,000. 70.90% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.